BNP PARIBAS ARBITRAGE, SA
Position in XERS — Xeris Biopharma Holdings, Inc.
CIK 1166588
NEW YORK, NY
Position in XERS
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$3,409,464
+$1,885,300 QoQ
Shares Held
430,488
+63.8% QoQ
Ownership
0.236%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#47
of 238 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in XERS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026BNP PARIBAS ARBITRAGE, SA holds $502,986,525 across 54 Drug Manufacturers - Specialty & Generic names. XERS ranks #21 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
1,415,471 | $101,715,746 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
260,605 | $43,922,366 | |
| 3 | RDY |
Dr Reddys Laboratories Ltd
|
2,649,866 | $38,396,558 | |
| 4 | ALKS |
Alkermes plc.
|
655,140 | $34,329,336 | |
| 5 | LNTH |
Lantheus Holdings, Inc.
|
300,967 | $33,389,278 | |
| 6 | UTHR |
UNITED THERAPEUTICS Corp
|
58,580 | $31,740,401 | |
| 7 | ELAN |
Elanco Animal Health Inc
|
1,180,709 | $29,057,248 | |
| 8 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
437,192 | $27,958,428 |
All Filings in XERS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,409,464 | 430,488 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $1,524,164 | 262,787 | Shares | Defined | 2026-05-12 | |
| 2025-12-31 | $2,028,188 | 258,368 | Shares | Defined | 2026-02-10 | |
| 2025-09-30 | $4,735,192 | 581,719 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $76,167 | 16,310 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $1,893,435 | 344,888 | Shares | Defined | 2025-05-14 | |
| 2024-12-31 | $339,040 | 100,012 | Shares | Defined | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||